{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T15:40:04Z","timestamp":1754149204316,"version":"3.41.2"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Glucagon-like peptide-1 (GLP-1) agonists, originally developed as a treatment for type 2 diabetes, have been increasingly shown to demonstrate benefits for patients within the realm of cardiovascular disease, such as patients with obesity and congestive heart failure. As rates of patients with these conditions climb, the prevalence of atrial fibrillation, one of the world\u2019s most common arrhythmias, has also increased. The goal of this literature review is to examine what, if any, links GLP-1 agonists may have in preventing or treating atrial fibrillation. To date, a number of meta-analyses have been conducted studying potential relationships between GLP-1 agonists and atrial fibrillation, but there has yet to be a randomized controlled trial fully exploring GLP-1\u2019s effects on atrial fibrillation.<\/jats:p>","DOI":"10.1097\/crd.0000000000001003","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T15:00:38Z","timestamp":1752850838000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Potential Therapeutic Benefits of Glucagon-Like-Peptide-1 Agonists and Atrial Fibrillation"],"prefix":"10.1097","author":[{"given":"Hall","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Maksymiuk","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"R1-20250718","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fphys.2019.00135","article-title":"The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights.","volume":"10","author":"Bohne","year":"2019","journal-title":"Front Physiol"},{"key":"R3-20250718","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials.","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"R4-20250718","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY).","volume":"65","author":"Pathak","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R5-20250718","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacbts.2023.01.005","article-title":"Glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice.","volume":"8","author":"Bohne","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"R6-20250718","doi-asserted-by":"crossref","first-page":"910256","DOI":"10.3389\/fendo.2022.910256","article-title":"Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"13","author":"Wei","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R7-20250718","first-page":"101218","article-title":"Effects of GLP-1 agonists on mortality and arrhythmias in patients with type II diabetes.","volume":"47","author":"Al-Sadawi","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R8-20250718","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jacep.2024.03.031","article-title":"Effects of glucagon-like Peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation.","volume":"10","author":"Satti","year":"2024","journal-title":"JACC Clin Electrophysiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T15:00:39Z","timestamp":1752850839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":7,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001003","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}